In a Phase 1 clinical study, researchers led by EPFL and their partners report that a new liver- and gut-targeted oral drug ...

Experimental drug slashes triglycerides and remnant cholesterol in trial, potentially filling gap for patients with ...

In a small, short-term, Phase 2 clinical trial in adults, a first-of-its-kind medication reduced triglyceride levels in most patients by more than 60%. Called DR10624, the medication activates three ...

Asharq Al Awsat A study led by researchers from the Ecole Polytechnique Fédérale de Lausanne (EPFL) in Switzerland, revealed ...

Amarin Corporation plc (NASDAQ: AMRN), a company advancing the science of cardiovascular therapeutics worldwide, today commented on recent innovations in therapies for patients with elevated ...

In a major new study, researchers from Intermountain Health in Salt Lake City have found that weight loss drugs used by patients who have high triglycerides do not increase their risk of pancreatitis ...

Familial chylomicronemia syndrome (FCS) is a rare genetic disease that causes very high triglyceride levels in the body. Tryngolza (olezarsen) was approved in 2024 and is the first and only ...

Tryngolza (olezarsen) is a prescription drug approved to lower triglyceride levels in adults with a certain genetic condition. Tryngolza comes as a liquid solution for injection under the skin.

Omega-3s may reduce the risk of high blood pressure, but fish oil may be more effective in people with high blood pressure or high triglycerides. Learn why.